| Expression pattern: |
UP |
| Associated gene: |
HLA-A*11:01 |
| Associated microRNA: |
- |
| Biological function: |
elicits antigen-specific CD8+ T cell response and expansion; enables recognition and elimination of CRC cells/tumor organoids via circRNA-derived neoepitopes |
| Molecular mechanism: |
circRNA translation into novel ORFs/peptides (neoepitopes) that bind HLA-A*11:01 and activate CD8+ T cells |
| Biological pathway or process: |
immune regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; divergent primers PCR; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; Luciferase Reporter Assay; ELISA; IF; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model |
| Clinical significance: |
potential candidate neoantigen source for cancer vaccines in CRC |
| Description: |
circRAPGEF5 is upregulated in CRC and encodes HLA-A*11:01-restricted neoepitopes from circRNA-specific ORFs. These peptides stimulate antigen-specific CD8+ T-cell responses, supporting circRAPGEF5 as a vaccine neoantigen source. |
| Confidence score: |
0.721 |